Company Overview of Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company’s lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinson’s disease; and in a Phase 2 clinical study for the treatment of symptoms associated with various sclerosis, including walking impairment. The company’s portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release ca...
1900 Powell Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Adamas Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $770.0K
Chief Medical Officer
Total Annual Compensation: $313.9K
Compensation as of Fiscal Year 2015.
Adamas Pharmaceuticals, Inc. Key Developments
Adamas Pharmaceuticals, Inc. to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017
Feb 17 17
Adamas Pharmaceuticals, Inc. will present results from its Phase 2 proof-of-concept study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of walking impairment in patients with multiple sclerosis (MS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2017. In the study, patients on ADS-5102 showed an approximate 17% placebo-adjusted improvement in walking speed in the Timed 25 Foot Walk (T25FW) test. Phase 2 Proof-of-Concept Study Design and Results. The multi-center, randomized, double-blind, placebo-controlled Phase 2 study was designed to evaluate ADS-5102 in MS patients with walking impairment for four weeks. The study enrolled 60 MS patients who had impaired walking speed at baseline. The primary study objective was to evaluate the safety and tolerability of 340 mg ADS-5102 dosed once daily at bedtime. Exploratory efficacy analyses included the change from baseline to week four in the T25FW, the TUG, the 2 Minute Walk Test (2MWT) and the Multiple Sclerosis Walking Scale-12 (MSWS-12). Efficacy results were obtained from a modified intent-to-treat population that included 56 subjects who received at least one dose of ADS-5102 and provided at least one post-baseline walking assessment. An analysis using the mean changes from baseline to week four efficacy measures showed an approximate 17% placebo-adjusted improvement in walking speed in the T25FW test. Walking impairment, which affects approximately 80% of diagnosed patients, is associated with an increased risk of falls and has a substantial impact on daily activities.
Adamas Pharmaceuticals, Inc. Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-Induced Dyskinesia in Patients
Jan 6 17
Adamas Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. The ADS-5102 application has been given a Prescription Drug User Fee Act (PDUFA) target action date of August 24, 2017. The NDA for ADS-5102 was submitted in October 2016 and is supported by efficacy and safety data compiled from Adamas' full clinical program, which was designed to evaluate ADS-5102 for the treatment of LID in patients with Parkinson's disease. The comprehensive program included three placebo-controlled trials: EASED and two Phase 3 trials, EASE LID and EASE LID 3. The controlled Phase 3 data for ADS-5102 presented in the NDA demonstrate a primary reduction of LID and a secondary reduction in OFF time in Parkinson’s disease patients, with a manageable safety and tolerability profile. The NDA is also supported by data from an open-label safety study known as EASE LID 2, which enrolled patients from EASED, EASE LID and EASE LID 3, as well as LID patients who have undergone deep brain stimulation. The EASE LID 2 trial is ongoing, and patients are being followed for up to two years.
Adamas Pharmaceuticals, Inc Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
Jan 3 17
Adamas Pharmaceuticals, Inc. announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in development for the treatment of partial onset seizures in patients with epilepsy. Derived from the company’s development platform, ADS-4101 is chrono-synchronous lacosamide, an anti-epilepsy active ingredient previously approved by the U.S. Food and Drug Administration (FDA) and currently marketed as VIMPAT®. There is an important need for new, clinically differentiated treatment options for epilepsy, a chronic neurologic disorder characterized by recurrent unprovoked seizures. Epilepsy affects an estimated 2.2 million Americansi. Nearly two-thirds of epilepsy patients suffer from partial onset seizures, which affect one side of the brain. Despite advances, nearly one-third of epilepsy patients continue to suffer from seizures. ADS-4101 is designed as a once-daily, new high strength lacosamide to provide a clinically meaningful and differentiated treatment option for epilepsy patients with partial onset seizures.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|